Paul Carpenter
Overview
Explore the profile of Paul Carpenter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rotz S, Hamilton B, Wei W, Ahmed I, Winston S, Ballard S, et al.
Transplant Cell Ther
. 2024 Feb;
30(5):534.e1-534.e13.
PMID: 38342136
The use of reduced-intensity conditioning (RIC) regimens has increased in an effort to minimize hematopoietic stem cell transplantation (HCT) end-organ toxicity, including gonadal toxicity. We aimed to describe the incidence...
2.
Liang E, Onstad L, Carpenter P, Pergam S, Flowers M, Lee S, et al.
Transplant Cell Ther
. 2023 Jul;
29(9):584.e1-584.e9.
PMID: 37394113
Hematopoietic cell transplantation (HCT) recipients experience significant morbidity and mortality from coronavirus disease 19 (COVID-19) infection. Data are limited regarding long-term HCT survivors' uptake of and experiences with COVID-19 vaccination...
3.
Im A, Pusic I, Onstad L, Kitko C, Hamilton B, Alousi A, et al.
Haematologica
. 2023 May;
109(1):143-150.
PMID: 37226713
Chronic graft-versus-host disease (GvHD) treatment response is assessed using National Institutes of Health (NIH) Consensus Criteria in clinical trials, and by clinician assessment in routine practice. Patient-reported treatment response is...
4.
DeFilipp Z, Ciurea S, Cutler C, Robin M, Warlick E, Nakamura R, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):71-81.
PMID: 36436780
The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated in the context of the evidence. Specific...
5.
Chen G, Onstad L, Martin P, Carpenter P, Pidala J, Arai S, et al.
Haematologica
. 2022 May;
108(2):483-489.
PMID: 35615925
Successful treatment of chronic graft-versus-host disease (GvHD) often requires long-term systemic therapy (ST). Durable discontinuation of ST reflects the resolution of active chronic GvHD. We evaluated the factors associated with...
6.
Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, et al.
Transplant Cell Ther
. 2022 Mar;
28(6):284-293.
PMID: 35306217
Over the past decade, therapeutic options in multiple myeloma (MM) have changed dramatically. Given the unprecedented efficacy of novel agents, the role of hematopoietic cell transplantation (HCT) in MM remains...
7.
Dahlberg A, Kurtzberg J, Boelens J, Martinez C, Carpenter P, Tewari P
Transplant Cell Ther
. 2021 Sep;
27(12):968-972.
PMID: 34571212
Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing...
8.
Pidala J, Kitko C, Lee S, Carpenter P, Cuvelier G, Holtan S, et al.
Transplant Cell Ther
. 2021 Apr;
27(8):632-641.
PMID: 33836313
Chronic graft-versus-host disease (GVHD) commonly occurs after allogeneic hematopoietic cell transplantation (HCT) despite standard prophylactic immune suppression. Intensified universal prophylaxis approaches are effective but risk possible overtreatment and may interfere...
9.
Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al.
Biol Blood Marrow Transplant
. 2020 Feb;
26(5):845-854.
PMID: 32018062
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) following hematopoietic cell transplantation (HSCT) is associated with poor clinical outcomes. Currently, there are no safe and effective therapies approved for use in the pediatric...
10.
Kanate A, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al.
JAMA Oncol
. 2019 Mar;
5(5):715-722.
PMID: 30816957
Importance: Maintenance therapies are often considered as a therapeutic strategy in patients with lymphoma following autologous hematopoietic cell transplantation (auto-HCT) to mitigate the risk of disease relapse. With an evolving...